Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
The Allurion Program is suited for people who are unable to achieve their weight-loss goals by dieting alone or for those who do not want to, or cannot, undergo invasive surgery or endoscopy
Despite having rich knowledge and defined responsibility, there has been less than expected response towards organ donation from our citizens
Healthcare has become more focused on innovation and technology over the past two years and 80% of healthcare systems are aiming to increase their investment in digital healthcare tools in the coming five years
In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Subscribe To Our Newsletter & Stay Updated
